Lexeo Therapeutics (LXEO) to Release Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) is projected to release its earnings data before the market opens on Monday, March 10th. Analysts expect Lexeo Therapeutics to post earnings of ($0.81) per share for the quarter.

Lexeo Therapeutics Price Performance

Shares of NASDAQ LXEO traded up $0.10 during trading on Thursday, reaching $2.81. The company had a trading volume of 385,275 shares, compared to its average volume of 357,274. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.50. The stock has a 50-day moving average price of $5.06 and a two-hundred day moving average price of $7.51. The stock has a market capitalization of $92.92 million, a PE ratio of -0.89 and a beta of 3.86.

Wall Street Analysts Forecast Growth

LXEO has been the subject of several analyst reports. Leerink Partners cut their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a research note on Wednesday, November 13th. HC Wainwright boosted their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a research report on Thursday, November 14th. Royal Bank of Canada restated an "outperform" rating and set a $24.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, January 21st. Finally, Chardan Capital lifted their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Lexeo Therapeutics presently has an average rating of "Buy" and a consensus target price of $23.80.

Remove Ads

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.